Dr. Omri Amirav-Drory is the General Partner at NFX Bio. With a background as both a scientist and entrepreneur, he has played a pivotal role in founding, scaling, and investing in influential techbio companies. He was the Founding CEO of Genome Compiler, where he developed software for genetic engineers and synthetic biologists. Under his leadership, Genome Compiler was successfully acquired by Twist Bioscience, a next-generation DNA synthesis company valued at approximately $2.5 billion. Following the acquisition, Omri served as the Head of Corporate Development at Twist for nearly three years, contributing significantly to the company's growth.

After his tenure at Twist, Omri co-founded Tech.Bio, where he invested in and advised numerous groundbreaking companies such as Mammoth Biosciences, Immunai, and C2i Genomics. His experience as a Scientist-CEO provides him with unique insights into the challenges and opportunities of techbio entrepreneurship. At NFX Bio, Omri is dedicated to fostering a future where the Scientist-CEO model becomes the standard, supporting innovative ventures at the intersection of technology and biology.